# Neurocrine Biosciences Inc. (NBIX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $16.68B  
**Price:** $162.71 (+1.15%)

> Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship product, INGREZZA (valbenazine), a VMAT2 inhibitor, addresses tardive dyskinesia and chorea associated with Huntington's disease, supported by extensive clinical data including long-term efficacy studies and head-to-head pharmacologic comparisons. The company also offers CRENESSITY alongside partnered products like ALKINDI SPRINKLE for adrenal insufficiency, Efemdy for classic congenital adrenal hyperplasia, and collaborations with AbbVie on Orilissa for endometriosis and Oriahnn for uterine fibroids. Neurocrine maintains a robust mid-to-late-stage pipeline featuring investigational therapies such as osavampator for major depressive disorder, direclidine for schizophrenia and bipolar mania, next-generation VMAT2 inhibitors like NBI-1065890 for tardive dyskinesia, and CRF-based programs targeting metabolic conditions including obesity. These efforts underscore its role in advancing therapies for complex movement disorders, psychiatric conditions, and endocrine diseases within the biopharmaceutical sector. Founded in 1992 and headquartered in San Diego, California, Neurocrine Biosciences Inc. plays a pivotal part in neuroscience innovation.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2.86B | $2.81B | $619M | $479M | — |
| 2024 | $2.36B | $2.32B | $571M | $341M | — |
| 2023 | $1.89B | $1.85B | $251M | $250M | — |
| 2022 | $1.49B | $1.47B | $249M | $155M | — |
| 2021 | $1.13B | $1.12B | $103M | $90M | — |
| 2020 | $1.05B | $1.04B | $163M | $407M | — |
| 2019 | $788M | — | $72M | $37M | — |
| 2018 | $451M | $446M | $37M | $21M | — |
| 2017 | $162M | $160M | -$131M | -$143M | — |
| 2016 | $15M | $15M | -$147M | -$141M | — |
| 2015 | $20M | $20M | -$94M | -$89M | — |
| 2014 | — | — | -$64M | -$61M | — |
| 2013 | $3M | — | -$50M | -$46M | — |
| 2012 | $53M | — | $1M | $5M | — |
| 2011 | $77M | — | $34M | $38M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4.63B | $1.38B | $3.25B | $713M | — |
| 2024 | $3.72B | $1.13B | $2.59B | $233M | — |
| 2023 | $3.25B | $1.02B | $2.23B | $251M | — |
| 2022 | $2.37B | $661M | $1.71B | $263M | — |
| 2021 | $2.07B | $699M | $1.37B | $341M | — |
| 2020 | $1.73B | $609M | $1.13B | $187M | — |
| 2019 | $1.31B | $669M | $637M | $112M | — |
| 2018 | $993M | $512M | $481M | $142M | — |
| 2017 | $818M | $445M | $372M | $255M | — |
| 2016 | $365M | $50M | $315M | $83M | — |
| 2015 | $475M | $50M | $424M | $74M | — |
| 2014 | $243M | $34M | $209M | $31M | — |
| 2013 | $155M | $34M | $120M | $45M | — |
| 2012 | $196M | $42M | $154M | $64M | — |
| 2011 | $138M | $78M | $60M | $50M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $783M | $34M | $749M |
| 2024 | $595M | $38M | $557M |
| 2023 | $390M | $28M | $362M |
| 2022 | $339M | $17M | $323M |
| 2021 | $257M | $23M | $233M |
| 2020 | $229M | $11M | $218M |
| 2019 | $147M | $15M | $132M |
| 2018 | $101M | $25M | $77M |
| 2017 | -$94M | $7M | -$101M |
| 2016 | -$106M | $4M | -$110M |
| 2013 | -$30M | $545,000 | -$30M |
| 2012 | -$35M | $971,000 | -$36M |
| 2011 | -$698,000 | $750,000 | -$1M |
| 2010 | $50M | $315,000 | $50M |
| 2009 | -$53M | $35,000 | -$53M |

Source: [CompaniesByCap](https://companiesbycap.com/company/NBIX)